inclusion criteria: 1. participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. 2. who clinical progression scale score \> 1 and \< 4. 3. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. 4. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. 5. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). 6. participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). 7. participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures. 8. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue through 90 days following administration of imp. 9. women of childbearing potential must use one highly effective form of birth control.

inclusion criteria: 1. participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. 2. who clinical progression scale score \> 1 and \< 4. 3. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. 4. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. 5. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). 6. participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). 7. participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures. 8. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue through 90 days following administration of imp. 9. women of childbearing potential must use one highly effective form of birth control.

inclusion criteria: participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. who clinical progression scale score > 1 and < 4. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue through 90 days following administration of imp. women of childbearing potential must use one highly effective form of birth control.

inclusion criteria: participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. who clinical progression scale score > 1 and < 4. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue through 90 days following administration of imp. women of childbearing potential must use one highly effective form of birth control.

inclusion criteria: 1. participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. 2. who clinical progression scale score > 1 and < 4. 3. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. 4. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. 5. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). 6. participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). 7. participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures. 8. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue through 90 days following administration of imp. 9. women of childbearing potential must use one highly effective form of birth control.

inclusion criteria: 1. participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. 2. who clinical progression scale score > 1 and < 4. 3. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. 4. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. 5. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). 6. participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). 7. participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures. 8. male participants: contraception for male participants is not required; however, to avoid the transfer of any fluids, all male participants must use a condom from day 1 and agree to continue through 90 days following administration of imp. 9. women of childbearing potential must use one highly effective form of birth control.

inclusion criteria: 1. participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. 2. who clinical progression scale score > 0 and < 4. 3. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. 4. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. 5. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). 6. participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). 7. participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures.

inclusion criteria: 1. participant has a documented laboratory-confirmed sars-cov-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (eg, oropharyngeal, np, or nasal swab, or saliva) collected ≤ 3 days prior to day 1. 2. who clinical progression scale score > 0 and < 4. 3. participant must be dosed with imp no more than 7 days from self-reported onset of covid-19-related symptoms (mild to moderate covid-19) or measured fever, defined as the self-reported date of first reported sign/symptom. 4. one or more of the following signs/symptoms must be present within 24 hours prior to day1: cough, sore throat, shortness of breath or difficulty breathing at rest or with activity, body pain or muscle pain/aches, fatigue, headache, chills, nasal obstruction or congestion, nasal discharge, nausea or vomiting, diarrhea, new loss of taste or smell. 5. oxygenation saturation of ≥ 92% obtained at rest by study staff within 24 hours prior to day 1 (unless participant regularly receives chronic supplementary oxygen for an underlying lung condition). 6. participant agrees not to participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period until reaching hospitalization or 28 days after entry into the study (whichever is earliest). 7. participant must be ≥ 18 years of age, provide informed consent and is able to comply with study requirements/procedures.